	US 11,752,176 B2
	Methods and compositions for enhancing cardiomyocyte maturation and engraftment
Charles E. Murry, Seattle, WA (US); Sanjay Sinha, Cambridge (GB); and Johannes Bargehr, Cambridge (GB)
Assigned to University of Washington, Seattle, WA (US); and Cambridge Enterprise Limited, Cambridge (GB)
Appl. No. 16/493,888
Filed by UNIVERSITY OF WASHINGTON, Seattle, WA (US); and CAMBRIDGE ENTERPRISE LIMITED, Cambridge (GB)
PCT Filed Mar. 15, 2018, PCT No. PCT/US2018/022659 § 371(c)(1), (2) Date Sep. 13, 2019, PCT Pub. No. WO2018/170280, PCT Pub. Date Sep. 20, 2018.
Claims priority of provisional application 62/471,737, filed on Mar. 15, 2017.
Prior Publication US 2020/0085880 A1, Mar. 19, 2020
Int. Cl. A61K 35/34 (2015.01); A61K 35/545 (2015.01); A61K 31/4409 (2006.01); A61K 38/13 (2006.01); A61K 38/30 (2006.01); A61P 9/10 (2006.01); A61P 9/04 (2006.01); C12N 5/00 (2006.01)

CPC A61K 35/34 (2013.01) [A61K 31/4409 (2013.01); A61K 35/545 (2013.01); A61K 38/13 (2013.01); A61K 38/30 (2013.01); A61P 9/04 (2018.01); A61P 9/10 (2018.01)]

15 Claims

1. A transplant composition comprising human cardiomyocytes and in vitro-differentiated human epicardial cells or the differentiated progeny of such human epicardial cells, wherein upon administration to cardiac tissue of a subject in need thereof, the cardiomyocytes, the epicardial cells and/or their differentiated progeny engraft into the cardiac tissue.